FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1831044128> ?p ?o ?g. }

• W1831044128 endingPage "3061" @default.
• W1831044128 startingPage "3056" @default.
• W1831044128 abstract "PURPOSE Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. PATIENTS AND METHODS Topotecan 1.5 mg/m2/d was administered intravenously by 30-minute infusion for 5 days repeated every 3 weeks. As the cisplatin-free interval relates to response in subsequent treatment, patients were stratified in subgroups, ie, cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive. RESULTS One-hundred eleven patients entered the study. Nineteen patients were considered to be ineligible; 92 patients were assessable for response. A total of 552 courses were given (median, four per patient; range, one to 17). The major toxicities were leukocytopenia and neutropenia, which were grade 3 to 4 in 54.2% and 69.1% of courses, respectively, but with only 4.3% of these being grade 4 neutropenia plus fever or infectious complications. Prophylactic granulocyte colony-stimulating factor (G-CSF) was given in 20.5% of courses to maintain dose-intensity. Other relatively frequent side effects were alopecia (82%), nausea (36.4%), and vomiting (17.5%). The overall response rate was 16.3%, with one complete response (CR) and 14 partial responses (PRs). In the cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive strata, the response rates were 5.9%, 17.8%, and 26.7%, respectively. The median duration of time of documented response was 21.7 weeks (range, 4.6 to 41.9). CONCLUSION Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer. Further investigations of topotecan in ovarian cancer, including first-line use and combination with other active agents, are indicated." @default.
• W1831044128 created "2016-06-24" @default.
• W1831044128 creator A5002774834 @default.
• W1831044128 creator A5005344356 @default.
• W1831044128 creator A5011819733 @default.
• W1831044128 creator A5014979681 @default.
• W1831044128 creator A5021427123 @default.
• W1831044128 creator A5032543018 @default.
• W1831044128 creator A5037672743 @default.
• W1831044128 creator A5042255432 @default.
• W1831044128 creator A5046199103 @default.
• W1831044128 creator A5049710331 @default.
• W1831044128 creator A5052811082 @default.
• W1831044128 creator A5069041063 @default.
• W1831044128 creator A5089385974 @default.
• W1831044128 date "1996-12-01" @default.
• W1831044128 modified "2023-10-15" @default.
• W1831044128 title "Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study." @default.
• W1831044128 cites W1845622004 @default.
• W1831044128 cites W1880772556 @default.
• W1831044128 cites W1956546108 @default.
• W1831044128 cites W1972483602 @default.
• W1831044128 cites W1981534406 @default.
• W1831044128 cites W2032165938 @default.
• W1831044128 cites W2066933615 @default.
• W1831044128 cites W2069885515 @default.
• W1831044128 cites W2088762946 @default.
• W1831044128 cites W2095355415 @default.
• W1831044128 cites W2096889436 @default.
• W1831044128 cites W2101100140 @default.
• W1831044128 cites W2108018389 @default.
• W1831044128 cites W2117729836 @default.
• W1831044128 cites W2137920066 @default.
• W1831044128 cites W2141258764 @default.
• W1831044128 cites W2154335454 @default.
• W1831044128 cites W2157867333 @default.
• W1831044128 cites W2159921901 @default.
• W1831044128 cites W2262251960 @default.
• W1831044128 cites W2282932528 @default.
• W1831044128 cites W2439761312 @default.
• W1831044128 doi "https://doi.org/10.1200/jco.1996.14.12.3056" @default.
• W1831044128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8955650" @default.
• W1831044128 hasPublicationYear "1996" @default.
• W1831044128 type Work @default.
• W1831044128 sameAs 1831044128 @default.
• W1831044128 citedByCount "354" @default.
• W1831044128 countsByYear W18310441282012 @default.
• W1831044128 countsByYear W18310441282013 @default.
• W1831044128 countsByYear W18310441282014 @default.
• W1831044128 countsByYear W18310441282015 @default.
• W1831044128 countsByYear W18310441282016 @default.
• W1831044128 countsByYear W18310441282017 @default.
• W1831044128 countsByYear W18310441282018 @default.
• W1831044128 countsByYear W18310441282019 @default.
• W1831044128 countsByYear W18310441282020 @default.
• W1831044128 countsByYear W18310441282021 @default.
• W1831044128 countsByYear W18310441282022 @default.
• W1831044128 countsByYear W18310441282023 @default.
• W1831044128 crossrefType "journal-article" @default.
• W1831044128 hasAuthorship W1831044128A5002774834 @default.
• W1831044128 hasAuthorship W1831044128A5005344356 @default.
• W1831044128 hasAuthorship W1831044128A5011819733 @default.
• W1831044128 hasAuthorship W1831044128A5014979681 @default.
• W1831044128 hasAuthorship W1831044128A5021427123 @default.
• W1831044128 hasAuthorship W1831044128A5032543018 @default.
• W1831044128 hasAuthorship W1831044128A5037672743 @default.
• W1831044128 hasAuthorship W1831044128A5042255432 @default.
• W1831044128 hasAuthorship W1831044128A5046199103 @default.
• W1831044128 hasAuthorship W1831044128A5049710331 @default.
• W1831044128 hasAuthorship W1831044128A5052811082 @default.
• W1831044128 hasAuthorship W1831044128A5069041063 @default.
• W1831044128 hasAuthorship W1831044128A5089385974 @default.
• W1831044128 hasConcept C121332964 @default.
• W1831044128 hasConcept C121608353 @default.
• W1831044128 hasConcept C126322002 @default.
• W1831044128 hasConcept C141071460 @default.
• W1831044128 hasConcept C142424586 @default.
• W1831044128 hasConcept C143998085 @default.
• W1831044128 hasConcept C2776694085 @default.
• W1831044128 hasConcept C2777063308 @default.
• W1831044128 hasConcept C2778239845 @default.
• W1831044128 hasConcept C2780427987 @default.
• W1831044128 hasConcept C2780580376 @default.
• W1831044128 hasConcept C2780852908 @default.
• W1831044128 hasConcept C2781209748 @default.
• W1831044128 hasConcept C2781413609 @default.
• W1831044128 hasConcept C2909463153 @default.
• W1831044128 hasConcept C31760486 @default.
• W1831044128 hasConcept C71924100 @default.
• W1831044128 hasConcept C87355193 @default.
• W1831044128 hasConcept C90924648 @default.
• W1831044128 hasConceptScore W1831044128C121332964 @default.
• W1831044128 hasConceptScore W1831044128C121608353 @default.
• W1831044128 hasConceptScore W1831044128C126322002 @default.
• W1831044128 hasConceptScore W1831044128C141071460 @default.
• W1831044128 hasConceptScore W1831044128C142424586 @default.
• W1831044128 hasConceptScore W1831044128C143998085 @default.
• W1831044128 hasConceptScore W1831044128C2776694085 @default.

• next